51894 Federal Register / Vol. 86, No. 178 / Friday, September 17, 2021 / Notices 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–20152 Filed 9–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

CDC announces the following meeting 

for the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). This 

meeting is open to the public, limited 

only by the webcast lines available. 

Check the CLIAC website on the day of 

the meeting for the web conference link 

www.cdc.gov/cliac. 

DATES: The meeting will be held on 

November 3, 2021, from 11:00 a.m. to 

6:00 p.m., EDT, and November 4, 2021, 

from 11:00 a.m. to 6:00 p.m., EDT. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials including instructions for 

accessing the live meeting broadcast 

will be available on the CLIAC website 

at www.cdc.gov/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Senior Advisor for Clinical Laboratories, 

Division of Laboratory Systems, Center 

for Surveillance, Epidemiology and 

Laboratory Services, Office of Public 

Health Scientific Services, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop V24–3, 

Atlanta, Georgia 30329–4027, 

Telephone: (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION:

Purpose: This Committee is charged 

with providing scientific and technical 

advice and guidance to the Secretary, 

HHS; the Assistant Secretary for Health; 

the Director, CDC; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendments of 

1988(CLIA) standards. Examples 

include providing guidance on studies 

designed to improve safety, 

effectiveness, efficiency, timeliness, 

equity, and patient-centeredness of 

laboratory services; revisions to the 

standards under which clinical 

laboratories are regulated; the impact of 

proposed revisions to the standards on 

medical and laboratory practice; and the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, the 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters To Be Considered: The agenda 

will include agency updates from CDC, 

CMS, and FDA. In addition to the 

general updates, agency presentations 

will include an overview of the FDA’s 

Center for Biologics Evaluation and 

Research, a laboratory safety update, 

and a status report on the new CLIA 

regulations assessment workgroup. 

Presentations and CLIAC discussion 

will focus on next generation 

sequencing in clinical and public health 

laboratories and laboratory data 

exchange and harmonization. Agenda 

items are subject to change as priorities 

dictate. 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person at least five business days prior 

to the meeting date. For individuals or 

groups unable to attend the meeting, 

CLIAC accepts written comments until 

the date of the meeting (unless 

otherwise stated). However, it is 

requested that comments be submitted 

at least five business days prior to the 

meeting date so that the comments may 

be made available to the Committee for 

their consideration and public 

distribution. All written comments will 

be included in the meeting Summary 

Report posted on the CLIAC website. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–20151 Filed 9–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–1274; Docket No. CDC–2021– 

0096] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on the 

Million Hearts Hospital & Health 

System Recognition Program. This 

program recognizes institutions working 

systematically to improve the 

cardiovascular health of the population 

and communities they serve. 

DATES: CDC must receive written 

comments on or before November 16, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0096 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600